Loading news...
Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Tandem Diabetes Care Inc. (NASDAQ: TNDM) stock is trading higher on Tuesday following an analyst upgrade, citing a long-term upside opportunity.
ArrowMark Colorado Holdings LLC lifted its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) by 36.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,691,198 shares of the medical device company's stock after purchasing an additional 991,649 shares during the
New pump launches, CGM integrations and strong solvency support Tandem Diabetes' growth outlook, though intense competition and macro headwinds remain risks.
Intech Investment Management LLC raised its position in shares of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) by 55.2% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 73,493 shares of the medical device company's stock after purchasing an additional 26,150 shares
SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world's smallest, durable automated insulin delivery system,1 can now be used with compatible Android smartphones in the U.S. via the Tandem Mobi mobile app. "By expanding to Android, we're broadening our reach to bring the benefits of Tandem Mobi to even more people living with diabetes," said John Sheridan, president and chief.
Tandem Diabetes Care (NASDAQ: TNDM) executives discussed recent operating performance and a broad set of strategic initiatives during a webcast event, emphasizing fourth-quarter execution improvements, an international sales model transition, upcoming product milestones, and a major shift in U.S. reimbursement through the pharmacy channel. Fourth-quarter momentum and margin expansion Management said the fourth quarter reflected multiple
Tandem Diabetes Care, Inc. (NASDAQ: TNDM - Get Free Report) has been given an average recommendation of "Hold" by the nineteen ratings firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, eleven have assigned a hold recommendation, six have assigned a buy recommendation and one has
Tandem Diabetes Care, Inc. (TNDM) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today the pricing of $265.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers under Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously a.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM - Get Free Report)'s share price rose 9% on Monday after Lake Street Capital upgraded the stock from a hold rating to a buy rating. Lake Street Capital now has a $50.00 price target on the stock. Tandem Diabetes Care traded as high as $27.92 and last traded at $26.7820.
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today that it intends to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of its Convertible Senior Notes due 2032 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “S.
Tandem Diabetes Care, Inc. delivered strong Q4 '25 results, with revenue and gross margin beats driving a 32% stock surge. TNDM's shift to a pay-as-you-go model will temporarily compress reported revenue but should enable smoother, recurring income and improved long-term economics.
Tandem saw robust demand for its insulin pumps in the fourth quarter. Management expects further shipment growth in 2026.
The stock is moving higher as the broader market is experiencing positive momentum, with the Nasdaq up 0.62% today, contributing to the bullish sentiment.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) reported better-than-expected fourth-quarter financial results on Thursday.
Tandem Diabetes tops Q4 estimates with narrower loss, 15% revenue jump and wider gross margin, sending shares up 6.7% after hours.
Tandem Diabetes Care, Inc. (TNDM) Q4 2025 Earnings Call Transcript
While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.44 per share a year ago.